Biosimilars
Undisclosed
Key Facts
About Mankind Pharma
Mankind Pharma is a dominant Indian pharmaceutical player with a mission to deliver affordable and accessible healthcare across the nation. Founded in 1995, it has achieved market leadership through deep penetration of underserved rural and semi-urban markets, supported by a company-owned distribution infrastructure. Its strategy is built on a diversified business model spanning formulations, consumer healthcare, APIs, and agritech, backed by significant R&D capabilities and manufacturing scale. The company is publicly traded and is recognized for its operational excellence and commitment to serving 'Bharat'.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| Amgen Collaboration Program | Xeris Biopharma | Pre-clinical |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |